BioAtla Investor Presentation Deck
Undifferentiated Pleomorphic Sarcoma (UPS):
Phase 1 & 2 Change in Target Lesion and Progression Free Survival (1.8mg/kg; n=8)
-20
-40
-60
-80
-100
100
80
60
40
20
Baseline
■
■
Week 6
■
Change Target Lesion From Baseline (%)
Week 12
Week 20
Week 28
Combo
Week 36
Week 44
Week 52
Week 60
Interim data- Data cut-off of April 28, 2022
Week 84
Week 92
Week 68
Week 76
Week 100
Progression Free Survival Probability
Number
at Risk
1.0
0.8
0.6
0.4
0.2
0.0
0
All Patient 8
T
1
8
T
2
7
T
3
3
T
4
3
Progression-free Survival
All Patients
T
5
3
6
T
7
Events
n(%)
5(62.5)
Median (mos)
(95% CI)
6.8 (1.4 - NE)
T
8 9 10 11 12 13 14
Months from First Dose
3 3 2 2 2 1 1 1 1
15
4/8 patients achieved PRs, with an ORR of 50% and PFS rate at 3 months of 50%
Responses to BA3011 treatment are durable, with partial responders remaining on treatment for extended periods of time
Interim results satisfied the pre-defined Go criteria of UPS cohort into part 2 of the Phase 2 study
bicatla
1
16
1
T
17
1
PFS 3mo
% (95% CI)
50.0 (15.2, 77.5)
18
T
19
1 1
1.
T
20 21
0 n/a
BioAtla| Overview
12View entire presentation